{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:22:38Z","timestamp":1760232158929,"version":"build-2065373602"},"reference-count":52,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AIFA (Agenzia Italiana del Farmaco)","award":["H56D15000500005"],"award-info":[{"award-number":["H56D15000500005"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Nowadays, novel oral anticoagulants (NOACs) have shown improved safety profile and efficacy compared to vitamin K antagonists in the prevention of thromboembolic events occurring during different pathological conditions. However, there are concerns and safety issues, mostly related to adverse events following interactions with other drugs, in real-world practice. We report the case of an 83-year-old woman who developed a non-bleeding leg ulcer not caused by trauma or other evident pathological conditions after 10 days of treatment with apixaban 5 mg\/q.d. She was switched from apixaban to dabigatran and the leg ulcer rapidly improved and completely cicatrized in 40 days. The resolution of the ulcer and the toleration of dabigatran therapy suggest an apixaban-specific reaction; however, the pathological mechanism of ulcer onset is currently unclear. Careful evaluation of hospital databases of Molise region (Southern Italy) hospitals identified two similar cases between 2019 and 2021. These cases underline the necessity of careful post-marketing surveillance, considering the rapidly increasing number of patients treated with NOACs and patient\u2019s risk factors such as old age, high polypharmacy rate, co-morbidities, and peculiar genetic background related to NOACs pharmacokinetic features.<\/jats:p>","DOI":"10.3390\/medicina58050691","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T03:16:55Z","timestamp":1653362215000},"page":"691","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cutaneous Ulcer Caused by Apixaban Treatment Is Resolved after Replacement with Dabigatran"],"prefix":"10.3390","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6285-607X","authenticated-orcid":false,"given":"Alessandro","family":"Medoro","sequence":"first","affiliation":[{"name":"Department of Medicine and Health Sciences \u201cV. Tiberio\u201d, University of Molise, 86100 Campobasso, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6145-2874","authenticated-orcid":false,"given":"Daniela","family":"Passarella","sequence":"additional","affiliation":[{"name":"Department of Medicine and Health Sciences \u201cV. Tiberio\u201d, University of Molise, 86100 Campobasso, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4314-056X","authenticated-orcid":false,"given":"Donatella","family":"Mignogna","sequence":"additional","affiliation":[{"name":"Department of Medicine and Health Sciences \u201cV. Tiberio\u201d, University of Molise, 86100 Campobasso, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8658-9909","authenticated-orcid":false,"given":"Carola","family":"Porcile","sequence":"additional","affiliation":[{"name":"Department of Medicine and Health Sciences \u201cV. Tiberio\u201d, University of Molise, 86100 Campobasso, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7150-9176","authenticated-orcid":false,"given":"Emanuele","family":"Foder\u00e0","sequence":"additional","affiliation":[{"name":"Department of Medicine and Health Sciences \u201cV. Tiberio\u201d, University of Molise, 86100 Campobasso, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Intrieri","sequence":"additional","affiliation":[{"name":"Department of Medicine and Health Sciences \u201cV. Tiberio\u201d, University of Molise, 86100 Campobasso, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0365-7430","authenticated-orcid":false,"given":"Gennaro","family":"Raimo","sequence":"additional","affiliation":[{"name":"Department of Medicine and Health Sciences \u201cV. Tiberio\u201d, University of Molise, 86100 Campobasso, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pancrazio","family":"La Floresta","sequence":"additional","affiliation":[{"name":"Department of Medicine and Health Sciences \u201cV. Tiberio\u201d, University of Molise, 86100 Campobasso, Italy"},{"name":"Orthopedics and Traumatology Unit, \u201cA. Cardarelli\u201d Hospital, Azienda Sanitaria Regionale del Molise, 86100 Campobasso, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2520-2958","authenticated-orcid":false,"given":"Claudio","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Medicine and Health Sciences \u201cV. Tiberio\u201d, University of Molise, 86100 Campobasso, Italy"},{"name":"UOC Governance del Farmaco, Azienda Sanitaria Regionale del Molise, 86100 Campobasso, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennaro","family":"Martucci","sequence":"additional","affiliation":[{"name":"Anesthesia and Intensive Care Unit, \u201cA. Cardarelli\u201d Hospital, Azienda Sanitaria Regionale del Molise, 86100 Campobasso, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2015.01.049","article-title":"Practical Management of Anticoagulation in Patients With Atrial Fibrillation","volume":"65","author":"Kovacs","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1161\/ATVBAHA.114.303396","article-title":"Clinical Experience With the New Oral Anticoagulants for Treatment of Venous Thromboembolism","volume":"35","author":"Bacchus","year":"2015","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/ATVBAHA.115.303397","article-title":"Overview of the New Oral Anticoagulants: Opportunities and Challenges","volume":"35","author":"Yeh","year":"2015","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1161\/STROKEAHA.111.000402","article-title":"Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation","volume":"44","author":"Harrington","year":"2013","journal-title":"Stroke"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1161\/CIRCULATIONAHA.112.115410","article-title":"Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-Analysis of the Literature","volume":"126","author":"Dentali","year":"2012","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.amjcard.2012.03.049","article-title":"Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation","volume":"110","author":"Miller","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"Antithrombotic Therapy for Atrial Fibrillation","volume":"141","author":"You","year":"2012","journal-title":"Chest"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","article-title":"Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","volume":"129","author":"Schulman","year":"2014","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Grosso","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral Rivaroxaban for Symptomatic Venous Thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1592\/phco.31.12.1232","article-title":"Dabigatran Etexilate in Clinical Practice: Confronting Challenges to Improve Safety and Effectiveness","volume":"31","author":"Gulseth","year":"2011","journal-title":"Pharmacotherapy"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1136\/bmj.h1857","article-title":"Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: Population based cohort study","volume":"350","author":"Abraham","year":"2015","journal-title":"BMJ"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s40264-016-0464-3","article-title":"Risk\u2013Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies","volume":"39","author":"Raschi","year":"2016","journal-title":"Drug Saf."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/bcp.13234","article-title":"Safety profile of the direct oral anticoagulants: An analysis of the WHO database of adverse drug reactions","volume":"83","author":"Monaco","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.20452\/pamw.3529","article-title":"Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: Beyond bleeding complications","volume":"126","author":"Raschi","year":"2016","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/0003319719874255","article-title":"Direct Anticoagulants and Risk of Myocardial Infarction, a Multiple Treatment Network Meta-Analysis","volume":"71","author":"Habon","year":"2020","journal-title":"Angiology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/MBC.0000000000000442","article-title":"Severe jaundice due to intrahepatic cholestasis after initiating anticoagulation with rivaroxaban","volume":"27","author":"Aslan","year":"2016","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1093\/ndt\/gft380","article-title":"Warfarin-related nephropathy is the tip of the iceberg: Direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats","volume":"29","author":"Ryan","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.14740\/jocmr3394w","article-title":"A Case of a Reversible Neurologic Adverse Reaction to Apixaban Confirmed by Re-Challenge","volume":"10","author":"Josyln","year":"2018","journal-title":"J. Clin. Med. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3389\/fneur.2018.01067","article-title":"Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs","volume":"9","author":"Galgani","year":"2018","journal-title":"Front. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00228-020-03015-7","article-title":"Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants\u2014A Swedish, register-based cohort study in atrial fibrillation outpatients","volume":"77","author":"Holm","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e203593","DOI":"10.1001\/jamanetworkopen.2020.3593","article-title":"Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function","volume":"3","author":"Pham","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s11239-020-02037-3","article-title":"The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding","volume":"49","author":"Hanigan","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1574886314666191003162104","article-title":"What are the Characteristics of Patients Experiencing Adverse Drug Reactions to Oral Anticogulants and How Can Such Reactions be Prevented?","volume":"15","author":"Spada","year":"2019","journal-title":"Curr. Drug Saf."},{"key":"ref_27","first-page":"196","article-title":"New Anticoagulant Agents: Incidence of Adverse Drug Reactions and New Signals Thereof","volume":"45","author":"Arias","year":"2018","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/0897190017722872","article-title":"Probable Rivaroxaban-Induced Full Body Rash: A Case Report","volume":"31","author":"Sasson","year":"2018","journal-title":"J. Pharm. Pract."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.amjmed.2016.06.004","article-title":"Safety of Direct Oral Anticoagulants: Insights from Postmarketing Studies","volume":"129","author":"Villines","year":"2016","journal-title":"Am. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.blre.2017.02.001","article-title":"Old and new oral anticoagulants: Food, herbal medicines and drug interactions","volume":"31","author":"Frigerio","year":"2017","journal-title":"Blood Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1002\/phar.1203","article-title":"Rash Associated with Dabigatran Etexilate","volume":"33","author":"To","year":"2013","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"ehw058","DOI":"10.1093\/eurheartj\/ehw058","article-title":"Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary","volume":"38","author":"Heidbuchel","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/107602960300900405","article-title":"The PAI-I gene 4G\/5G Polymorphism and Deep Vein Thrombosis in Patients with Inherited Thrombophilia","volume":"9","author":"Sartori","year":"2003","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000480447","article-title":"MTHFR A1298C and C677T Polymorphisms Are Associated with Increased Risk of Venous Thromboembolism: A Retrospective Chart Review Study","volume":"138","author":"Liu","year":"2017","journal-title":"Acta Haematol."},{"key":"ref_35","unstructured":"(2022, April 04). FDAble: Search FDA MedWatch FAERS AERS Database n.d.. Available online: http:\/\/www.fdable.com\/advanced_aers_query\/1445e394afeb6dabbb44e5d2f2e98635."},{"key":"ref_36","first-page":"213","article-title":"A rare side effect seen due to the use of apixaban: Palmoplantar psoriasiform drug eruption","volume":"16","author":"Veliyev","year":"2016","journal-title":"Anatol. J. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_38","unstructured":"(2013). The Use of the WHO-UMC System for Standardised Case Causality Assessment, World Health Organization (WHO)\u2013Uppsala Monitoring Centre."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/iwj.13563","article-title":"Livedoid vasculopathy and its association with genetic variants: A systematic review","volume":"18","author":"Gao","year":"2021","journal-title":"Int. Wound J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Shnayder, N., Petrova, M., Shesternya, P., Savinova, A., Bochanova, E., Zimnitskaya, O., Pozhilenkova, E., and Nasyrova, R. (2021). Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions. Biomedicines, 9.","DOI":"10.5772\/intechopen.95966"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2174\/092986707780090981","article-title":"The effect of ageing on cytochrome p450 enzymes: Consequences for drug biotransformation in the elderly","volume":"14","author":"Wauthier","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans","volume":"36","author":"Blech","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1021\/js970316d","article-title":"Pharmacokinetics and Metabolism of Bisoprolol Enantiomers in Humans","volume":"87","author":"Horikiri","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/00498250410001685728","article-title":"Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: Evaluation of an approach based on thein vitrosubstrate disappearance rate","volume":"34","author":"Naritomi","year":"2004","journal-title":"Xenobiotica"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1211\/jpp.61.01.0007","article-title":"Effects of cytochrome P450 inducers and inhibitors on the pharmacokinetics of intravenous furosemide in rats: Involvement of CYP2C11, 2E1, 3A1 and 3A2 in furosemide metabolism","volume":"61","author":"Yang","year":"2008","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2133\/dmpk.23.340","article-title":"Directional Transcellular Transport of Bisoprolol in P-glycoprotein-expressed LLC-GA5-COL150 Cells but not in Renal Epithelial LLC-PK1 Cells","volume":"23","author":"Tahara","year":"2008","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1097\/MJT.0000000000000786","article-title":"Effect of Bisoprolol on the Level of Dabigatran","volume":"27","author":"Nehaj","year":"2020","journal-title":"Am. J. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1211\/0022357043941","article-title":"Concentration dependency of modulatory effect of amlodipine on P-glycoprotein efflux activity of doxorubicin\u2014A comparison with tamoxifen","volume":"56","author":"Darvari","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1023\/A:1007568811691","article-title":"Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: Comparison with the effects on CYP3A4","volume":"17","author":"Katoh","year":"2000","journal-title":"Pharm. Res."},{"key":"ref_51","first-page":"157","article-title":"Effects of ABCB1 rs1045642 polymorphisms on the efficacy and safety of amlodipine therapy in Caucasian patients with stage I\u2013II hypertension","volume":"11","author":"Sychev","year":"2018","journal-title":"Pharm. Pers. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cjco.2021.11.002","article-title":"Amiodarone, Verapamil, or Diltiazem Use With Direct Oral Anticoagulants and the Risk of Hemorrhage in Older Adults","volume":"4","author":"Hill","year":"2021","journal-title":"CJC Open"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/5\/691\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:17:05Z","timestamp":1760138225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/5\/691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["medicina58050691"],"URL":"https:\/\/doi.org\/10.3390\/medicina58050691","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2022,5,23]]}}}